Alternative therapies for recurrent cystitis in menopausal women
Worldwide, urinary tract infections (UTIs) are reported in 150-250 million people per year. Annual direct and indirect costs of UTIs for overall patients are estimated to be from $2.4 billion to $3.5 billion Uropathogenic Escherichia coli is the most common cause of UTIs. These bacteria have the abi...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2022-08-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/7034 |
| _version_ | 1797841536851902464 |
|---|---|
| author | E. V. Kulchavenya L. S. Treyvish E. V. Telina |
| author_facet | E. V. Kulchavenya L. S. Treyvish E. V. Telina |
| author_sort | E. V. Kulchavenya |
| collection | DOAJ |
| description | Worldwide, urinary tract infections (UTIs) are reported in 150-250 million people per year. Annual direct and indirect costs of UTIs for overall patients are estimated to be from $2.4 billion to $3.5 billion Uropathogenic Escherichia coli is the most common cause of UTIs. These bacteria have the ability to colonize urothelium, persist in epithelial cells, and form quiescent biofilms. This bacterial reservoir may provide a source for bacterial persistence and UTIs recurrence. Besides, recurrent UTIs may be caused by the translocation of other bacteria which originate from the gastrointestinal tract or reinfections due to external sources. Menopause and pregnancy are considered as complicating factors that predispose to UTIs. Oral vaccine OM-89 and D-mannose are specified in the European Urological Association guidelines among non-pharmacological methods for the prevention of recurrent UTIs in postmenopausal women. The rationale to the use of D-mannose in UTI prophylaxis is based on its competitive inhibition of bacterial adherence to urothelial cells due to binding of type 1 fimbriae expressed on the bacteria. Exogenous D-mannose is absorbed, but not metabolized by the human body and it is excreted intact in urine. In vivo and in vitro studies showed the ability of mannose-like molecules to provide a 2-fold reduction of bacterial load in the urinary tract after 4 intravesical instillations. Clinical studies also demonstrated a high efficacy of the six months course of oral mannose in the prevention of UTIs. |
| first_indexed | 2024-04-09T16:32:35Z |
| format | Article |
| id | doaj.art-fce1138f99d34cefbca443245b79140a |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:32:35Z |
| publishDate | 2022-08-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-fce1138f99d34cefbca443245b79140a2023-04-23T06:57:02ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902022-08-0101416417010.21518/2079-701X-2022-16-14-164-1706296Alternative therapies for recurrent cystitis in menopausal womenE. V. Kulchavenya0L. S. Treyvish1E. V. Telina2Novosibirsk Tuberculosis Research Institute; Novosibirsk State Medical University; Medical Center “Avicenna”Medical Center “Avicenna”Medical Center “Avicenna”Worldwide, urinary tract infections (UTIs) are reported in 150-250 million people per year. Annual direct and indirect costs of UTIs for overall patients are estimated to be from $2.4 billion to $3.5 billion Uropathogenic Escherichia coli is the most common cause of UTIs. These bacteria have the ability to colonize urothelium, persist in epithelial cells, and form quiescent biofilms. This bacterial reservoir may provide a source for bacterial persistence and UTIs recurrence. Besides, recurrent UTIs may be caused by the translocation of other bacteria which originate from the gastrointestinal tract or reinfections due to external sources. Menopause and pregnancy are considered as complicating factors that predispose to UTIs. Oral vaccine OM-89 and D-mannose are specified in the European Urological Association guidelines among non-pharmacological methods for the prevention of recurrent UTIs in postmenopausal women. The rationale to the use of D-mannose in UTI prophylaxis is based on its competitive inhibition of bacterial adherence to urothelial cells due to binding of type 1 fimbriae expressed on the bacteria. Exogenous D-mannose is absorbed, but not metabolized by the human body and it is excreted intact in urine. In vivo and in vitro studies showed the ability of mannose-like molecules to provide a 2-fold reduction of bacterial load in the urinary tract after 4 intravesical instillations. Clinical studies also demonstrated a high efficacy of the six months course of oral mannose in the prevention of UTIs.https://www.med-sovet.pro/jour/article/view/7034menopauseurogenital syndromecystitischronic cystitisd-mannoseurogenital infections |
| spellingShingle | E. V. Kulchavenya L. S. Treyvish E. V. Telina Alternative therapies for recurrent cystitis in menopausal women Медицинский совет menopause urogenital syndrome cystitis chronic cystitis d-mannose urogenital infections |
| title | Alternative therapies for recurrent cystitis in menopausal women |
| title_full | Alternative therapies for recurrent cystitis in menopausal women |
| title_fullStr | Alternative therapies for recurrent cystitis in menopausal women |
| title_full_unstemmed | Alternative therapies for recurrent cystitis in menopausal women |
| title_short | Alternative therapies for recurrent cystitis in menopausal women |
| title_sort | alternative therapies for recurrent cystitis in menopausal women |
| topic | menopause urogenital syndrome cystitis chronic cystitis d-mannose urogenital infections |
| url | https://www.med-sovet.pro/jour/article/view/7034 |
| work_keys_str_mv | AT evkulchavenya alternativetherapiesforrecurrentcystitisinmenopausalwomen AT lstreyvish alternativetherapiesforrecurrentcystitisinmenopausalwomen AT evtelina alternativetherapiesforrecurrentcystitisinmenopausalwomen |